Medicinal Chemistry Strategies for the Discovery of Novel Antiviral Agents

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 315

Special Issue Editors

Center for Advanced Biotechnology and Medicine and Department of Chemistry and Chemical Biology, Rutgers University, New Brunswick, NJ, USA
Interests: structural biology; biochemistry; drug discovery; viral protein
Special Issues, Collections and Topics in MDPI journals
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China
Interests: medicinal chemistry; antiviral; drug design; drug resistant

Special Issue Information

Dear Colleagues,

Viral infections continue to be a serious threat to human health worldwide. According to data released by the World Health Organization (WHO), there are millions of deaths each year due to viral infections, especially since the outbreak of the coronavirus disease 2019 (COVID-19). During the past few decades, significant progress has been made in the field of antiviral drug discovery. However, current antiviral drugs cannot meet all clinical demands, and preparations need to be made for future threats posed by emerging viral pandemics. Therefore, in the current landscape of antiviral options, there remains an urgent need for novel antiviral agents with potent inhibitory activities and favorable safety profiles.

In this Special Issue, we welcome high-quality original research and review articles on antiviral drug discovery. Researchers can share their interesting work and perspectives on the discovery and development of antiviral drugs using state-of-the-art medicinal chemistry strategies; papers can include but are not limited to the following traditional and innovative antiviral strategies used to block viral infections:

  1. Structure-Based Design Strategy;
  2. Computer-Aided Drug Design;
  3. Natural Products Diversification;
  4. Targeted Covalent Inhibitors;
  5. Virtual Screening Approach;
  6. Phenotypic Screening Approach;
  7. Chimeric Bifunctional Molecules;
  8. Multitarget-Directed Ligands;
  9. Drug Repositioning Strategy;
  10. Host-Targeting Antiviral Agents.

Dr. Francesc Xavier Ruiz
Dr. Zhao Wang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • medicinal chemistry
  • structural biology
  • antiviral target
  • drug design
  • biological evaluation
  • novel technology

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop